Clinical Trial Search

Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants

Primary: Frequency of Adverse Events — 41 participants

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection — 134; 449; 46; 160 participants

Primary: Number of Participants With Adverse Events — 99 Participants

Primary: Incidence of RSV Hospitalization (Includes Deaths by RSV) — 62; 46 Participants

Primary: Number of Injections Per Patient Per Season — 3.8; 3.9; 4.0; 1.0 Injections administered

Primary: Percentage of Participants With RSV Hospitalization — 0.0 percentage of participants

Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants

Primary: Occurrences of Pneumonia — 4; 3 Participants

Primary: Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test — 1 participants

Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change

Primary: Mean Serum Concentrations (Cmax) for Open-label Palivizumab (Part 1) on Day 12. — 71.2 μg/mL

Primary: Area Under the Curve (AUC) for RSV-A Memphis 37b Viral Load Determined by Quantitative Real Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) — 350.99…

Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72

Primary: Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9 — -1.00; -0.97 log10 copies/mL — p=0.94

Primary: Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 — -0.77; -0.89 log10 copies/mL — p=0.46

Primary: Respiratory Syncytial Virus (RSV) Load in the Upper Respiratory Tract as Measured by Quantitative Real Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) at…

Primary: Percentage of Participants With RSV-associated Hospitalization — 1.5; 1.5; 0.8; 0.7 percentage of participants

Primary: Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 — -1.26; -0.91 log10 copies/mL — p=0.040

Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season…

Primary: Part A: Serum Concentration of Suptavumab Over Time — 280; 177; 145; 128 mg/L

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0 participants

Primary: Number of Subjects Reporting Adverse Events Through 30 Days After Dosing — 3; 5; 3; 6 Participants

Primary: Area Under the Viral Load-Time Curve (VL-AUC) of Respiratory Syncytial Virus (RSV) by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) — 0; 236…

Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6

Primary: Number of Subjects Reporting Serious Adverse Events (SAEs) — 19; 7; 11 participants

Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Hospitalization — 80; 21 Participants — p=<0.001

Primary: Number of Participants Who Experienced the Occurrence of a Third Episode of Post-RSV Wheezing (Recurrent Wheeze) — 45; 33 Participants — p=0.08

Primary: Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)…